2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neuroendocrine Tumors
10
Gastro-enteropancreatic neuroendocrine tumor
4
Pheochromocytoma
2
Paraganglioma
2
Vipoma
1
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Meningioma
1
Lymphoma
1
Insulinoma
1
Gastrinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoid Tumor
1
Interventions
pembrolizumab
29
avelumab
21
Nivolumab
20
Ipilimumab
10
Radiotherapy
9
Cyclophosphamide
9
atezolizumab
8
cemiplimab
7
fludarabine
6
Specimen Handling
6
durvalumab
5
aldesleukin
5
Radiation
5
Magnetic Resonance Spectroscopy
5
Interleukin-2
5
Biopsy
5
talimogene laherparepvec
4
ALT-803
4
poly ICLC
3
Radiosurgery
3
Etoposide
3
Cisplatin
3
Carboplatin
3
CTLA-4 Antigen
3
Bevacizumab
3
prednylidene
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
domatinostat
2
deltacortene
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT04276597
2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2
Withdrawn